Extended Versus Intermittent Meropenem Infusion in the Treatment of Nosocomial Pneumonia: A Retrospective Single-Center Study

The efficacy of extended meropenem infusions in patients with nosocomial pneumonia is not well defined. Therefore, we compared the clinical outcomes of extended versus intermittent meropenem infusions in the treatment of nosocomial pneumonia. We performed a retrospective analysis of extended versus...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel) 2023-10, Vol.12 (10), p.1542
Main Authors: Hyun, Dong-gon, Seo, Jarim, Lee, Su Yeon, Ahn, Jee Hwan, Hong, Sang-Bum, Lim, Chae-Man, Koh, Younsuck, Huh, Jin Won
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Bacteria
Bacterial pneumonia
Cancer therapies
Clinical outcomes
Drug resistance
Drug therapy
Empirical analysis
Health aspects
Health services
Hospitals
intensive care unit
intravenous infusion
Meropenem
Mortality
Nosocomial infection
Nosocomial infections
Pathogens
Patients
Pneumonia
Sepsis
Sputum
Subgroups
Tazobactam
ventilator-associated pneumonia
Ventilators
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of extended meropenem infusions in patients with nosocomial pneumonia is not well defined. Therefore, we compared the clinical outcomes of extended versus intermittent meropenem infusions in the treatment of nosocomial pneumonia. We performed a retrospective analysis of extended versus intermittent meropenem infusions in adult patients who had been treated for nosocomial pneumonia at a medical ICU between 1 May 2018 and 30 April 2020. The primary outcome was mortality at 14 days. Overall, 64 patients who underwent an extended infusion and 97 with an intermittent infusion were included in this study. At 14 days, 10 (15.6%) patients in the extended group and 22 (22.7%) in the intermittent group had died (adjusted hazard ratio (HR), 0.55; 95% confidence interval (CI): 0.23–1.31; p = 0.174). In the subgroup analysis, significant differences in mortality at day 14 were observed in patients following empirical treatment with meropenem (adjusted HR, 0.17; 95% CI: 0.03–0.96; p = 0.045) and in Gram-negative pathogens identified by blood or sputum cultures (adjusted HR, 0.01; 95% CI: 0.01–0.83; p = 0.033). Extended infusion of meropenem compared with intermittent infusion as a treatment option for nosocomial pneumonia may have a potential advantage in specific populations.
ISSN:2079-6382
2079-6382
DOI:10.3390/antibiotics12101542